Insights And Considerations From The Invalidation Case As To Ruxolitinib

Ruxolitinib, a selective JAK1/JAK2 inhibitor developed by Incyte Corporation, works by blocking the JAK-STAT signalling pathway, which is closely associated with the pathogenesis of various inflammatory diseases and myeloproliferative neoplasms (MPNs). Ruxolitinib was first approved for marketing in the United States in November 2011, for treating intermediate- to high-risk myelofibrosis (MF), and subsequently approved in the United States for treating hydroxyurea-resistant/intolerant polycythaemia vera (PV) (in December 2014), steroid-refractory acute graft-versus-host disease (GVHD) in patients aged 12 years and older (in May 2019), steroid-refractory chronic GVHD (in September 2021), atopic dermatitis (Opzelura", 1.5% cream, the first topical JAK inhibitor, in December 2021). In March 2017, Ruxolitinib was launched in China for treating intermediate- to high-risk MF.